Investment Strategy 2

When refining our position on high risk assets such as early stage biotech stock, it’s essential that we can have clarity and confidence in both the opportunity and threats these present. Eradigm’s team proved invaluable in dissecting complex data sets, formulating new hypotheses and testing these with a creative range of trusted sources